Leede Financial Issues Optimistic Forecast for ONCY Earnings

Oncolytics Biotech Inc. (NASDAQ:ONCY) – Analysts at Leede Financial lifted their FY2025 earnings per share (EPS) estimates for Oncolytics Biotech in a research report issued to clients and investors on Monday, March 10th. Leede Financial analyst D. Loe now forecasts that the company will post earnings of ($0.28) per share for the year, up from their previous forecast of ($0.29). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.28) per share. Leede Financial also issued estimates for Oncolytics Biotech’s FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at ($0.26) EPS and FY2029 earnings at ($0.09) EPS.

Several other equities analysts have also issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Oncolytics Biotech in a report on Monday, March 10th. Royal Bank of Canada dropped their target price on Oncolytics Biotech from $6.00 to $5.00 and set an “outperform” rating on the stock in a research note on Monday, March 10th. Finally, Maxim Group reduced their target price on Oncolytics Biotech from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Three equities research analysts have rated the stock with a buy rating, According to MarketBeat, Oncolytics Biotech presently has an average rating of “Buy” and a consensus price target of $4.00.

Oncolytics Biotech Stock Up 0.3 %

NASDAQ ONCY opened at $0.63 on Thursday. Oncolytics Biotech has a 52 week low of $0.58 and a 52 week high of $1.53. The company has a 50 day moving average price of $0.76 and a 200 day moving average price of $0.92. The firm has a market cap of $53.44 million, a PE ratio of -2.31 and a beta of 1.18.

Institutional Investors Weigh In On Oncolytics Biotech

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in shares of Oncolytics Biotech by 59.6% in the fourth quarter. Geode Capital Management LLC now owns 66,939 shares of the company’s stock worth $61,000 after purchasing an additional 24,997 shares during the last quarter. International Assets Investment Management LLC increased its holdings in Oncolytics Biotech by 15.0% in the 4th quarter. International Assets Investment Management LLC now owns 200,400 shares of the company’s stock worth $186,000 after buying an additional 26,069 shares during the period. Vantage Point Financial LLC purchased a new position in Oncolytics Biotech during the 4th quarter worth approximately $27,000. National Bank of Canada FI raised its position in Oncolytics Biotech by 199.6% during the 4th quarter. National Bank of Canada FI now owns 64,479 shares of the company’s stock worth $60,000 after buying an additional 42,955 shares during the last quarter. Finally, Virtu Financial LLC acquired a new stake in Oncolytics Biotech during the 4th quarter valued at approximately $90,000. 6.82% of the stock is currently owned by institutional investors and hedge funds.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.